¹⁸F-PSMA-1007与⁶⁸Ga-PSMA-11 PET/CT前列腺内肿瘤检测的头对头比较
这项前瞻性单中心诊断准确性研究以组织病理为参考标准,比较[¹⁸F]F-PSMA-1007 PET/CT、[⁶⁸Ga]Ga-PSMA-11 PET/CT与mpMRI对前列腺内肿瘤定位及临床显著前列腺癌(csPC)检测的表现。PSMA PET两种显像剂灵敏度均显著高于mpMRI,但特异性低于mpMRI;两种PSMA显像剂间未见显著差异。
要点
- 患者水平csPC检测灵敏度:[¹⁸F]F-PSMA-1007 98%、[⁶⁸Ga]Ga-PSMA-11 100%、mpMRI 96%。
- 前列腺六分区水平准确率:[¹⁸F]F-PSMA-1007 69.8%、[⁶⁸Ga]Ga-PSMA-11 67.8%、mpMRI 62.9%。
- PSMA PET灵敏度显著高于mpMRI(p<0.001),mpMRI特异性更高(p=0.002)。
核心结论
- PSMA PET/CT两种显像剂对前列腺内肿瘤定位的灵敏度高于mpMRI,但特异性较低。
- 本队列中[¹⁸F]F-PSMA-1007与[⁶⁸Ga]Ga-PSMA-11诊断表现未见统计学显著差异。
- 结果支持PSMA PET与mpMRI在高危前列腺癌术前前列腺内定位中可能互补。
研究设计与样本
- 前瞻性单中心诊断准确性研究,纳入活检证实高危前列腺癌并接受根治性前列腺切除术的患者。
- 所有患者行[¹⁸F]F-PSMA-1007 PET/CT和[⁶⁸Ga]Ga-PSMA-11 PET/CT,方案修订后部分患者术前加做mpMRI作为次要探索性影像。
- 以组织病理为参考标准,csPC定义为≥ISUP3或ISUP2伴三级Gleason 5模式。
- 按患者和前列腺六分区进行诊断性能评估,采用混合回归模型处理聚类效应。
主要发现
- 患者水平csPC检测灵敏度分别为98%、100%、96%,诊断准确率分别为96%、98%、93%([¹⁸F]F-PSMA-1007、[⁶⁸Ga]Ga-PSMA-11、mpMRI)。
- 300个六分区中205个含csPC;[¹⁸F]F-PSMA-1007识别143/300个分区(准确率69.8%,95%CI 64.0-75.6)。
- [⁶⁸Ga]Ga-PSMA-11检测136/300个分区(准确率67.8%,95%CI 62.3-73.4);mpMRI识别89/270个分区(准确率62.9%,95%CI 56.3-69.4)。
- EPE灵敏度分别为12%、23%、9%,SVI灵敏度分别为30%、30%、14%([¹⁸F]F-PSMA-1007、[⁶⁸Ga]Ga-PSMA-11、mpMRI)。
关键数值与推荐
- csPC定义:≥ISUP3或ISUP2伴三级Gleason 5模式。
- PSMA PET灵敏度显著高于mpMRI(p<0.001),mpMRI特异性更高(p=0.002)。
- 两种PSMA显像剂间未见显著差异;各模态对EPE和SVI检测灵敏度均有限。
临床怎么用
- 在高危前列腺癌术前评估中,PSMA PET/CT可提供较高的csPC检测灵敏度,但需结合mpMRI的特异性优势。
- 两种PSMA显像剂在本队列中表现相近,选择时可综合可及性与流程因素。
- 对EPE和SVI的术前判断不应单独依赖PSMA PET或mpMRI,各模态灵敏度均有限。
局限性
- mpMRI为方案修订后加入的次要探索性影像,仅在部分患者中完成。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA) PET has emerged as a sensitive imaging modality for prostate cancer (PC), but its role in intraprostatic tumour localisation relative to multiparametric MRI (mpMRI) and differences between [¹⁸F]- and [⁶⁸Ga]-PSMA ligands remain unclear. This study compared the diagnostic performance of [¹⁸F]F-PSMA-1007 PET/CT, [⁶⁸Ga]Ga-PSMA-11 PET/CT, and mpMRI for intraprostatic tumour localisation and detection of clinically significant prostate cancer (csPC). METHODS: In this prospective single-centre study, patients with biopsy-proven high-risk PC undergoing radical prostatectomy were recruited. All patients underwent [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT. Following a protocol amendment, mpMRI was added as a secondary exploratory imaging modality and performed in a subset of patients prior to surgery. Histopathology was the reference standard; csPC was defined as ≥ISUP3 or ISUP2 with tertiary Gleason 5 pattern. Diagnostic performance was assessed on a per-patient and per-region basis, dividing the prostate into sextants and using mixed regression models to account for clustering. Secondary analyses evaluated the detection of pathological features beyond the prostate, including extraprostatic extension (EPE) and seminal vesicle invasion (SVI). RESULTS: Fifty patients were included in the analysis of PSMA PET/CT, and 45 patients had mpMRI. At the patient level, [¹⁸F]F-PSMA-1007 PET/CT, [⁶⁸Ga]Ga-PSMA-11 PET/CT and mpMRI demonstrated sensitivities of 98%, 100%, and 96%, respectively, for the detection of csPC, with corresponding diagnostic accuracies of 96%, 98%, and 93%, respectively. Of 300 sextants, 205 contained csPC. [¹⁸F]F-PSMA-1007 PET/CT identified csPC in 143/300 sextants (accuracy: 69.8%, 95%CI 64.0-75.6). [⁶⁸Ga]Ga-PSMA-11 PET/CT detected csPC in 136/300 sextants (accuracy: 67.8%, 95%CI 62.3-73.4). mpMRI identified csPC in 89/270 sextants (accuracy: 62.9%, 95%CI 56.3-69.4). PSMA PET ligands showed significantly higher sensitivity than mpMRI (p < 0.001), whereas mpMRI demonstrated higher specificity (p = 0.002). No significant differences were observed between [¹⁸F]F-PSMA-1007 and [⁶⁸Ga]Ga-PSMA-11. Detection of pathological features of local tumour extension was limited across all modalities. Sensitivity for EPE was 12%, 23%, and 9%, and sensitivity for SVI was 30%, 30%, and 14% for [¹⁸F]F-PSMA-1007 PET/CT, [⁶⁸Ga]Ga-PSMA-11 PET/CT, and mpMRI, respectively. CONCLUSION: PSMA PET/CT ligands provide higher sensitivity than mpMRI for intraprostatic tumour localisation, while no statistically significant differences in diagnostic performance were detected between [¹⁸F]- and [⁶⁸Ga]-PSMA ligands in this cohort. These findings support the potential complementary role of PSMA PET and mpMRI for preoperative intraprostatic tumour localisation in high-risk PC.
引用
- Gossili F, Harving F, Petersen AC, et al. Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42762314. doi:10.1007/s00259-026-08191-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。